B. Riley Expects Stronger Earnings for Eton Pharmaceuticals

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Investment analysts at B. Riley increased their Q1 2025 earnings estimates for Eton Pharmaceuticals in a research note issued to investors on Sunday, April 27th. B. Riley analyst M. El-Saadi now expects that the company will post earnings of $0.13 per share for the quarter, up from their prior forecast of $0.06. B. Riley has a “Buy” rating and a $24.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is ($0.14) per share. B. Riley also issued estimates for Eton Pharmaceuticals’ Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at $0.11 EPS, FY2025 earnings at $0.64 EPS, FY2026 earnings at $1.48 EPS, FY2027 earnings at $1.86 EPS, FY2028 earnings at $2.23 EPS and FY2029 earnings at $2.46 EPS.

Other analysts also recently issued reports about the company. Craig Hallum boosted their price target on Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, March 19th. HC Wainwright reissued a “buy” rating and set a $33.00 target price on shares of Eton Pharmaceuticals in a report on Wednesday, March 19th.

Eton Pharmaceuticals Stock Up 0.7 %

Shares of NASDAQ:ETON opened at $16.97 on Wednesday. Eton Pharmaceuticals has a 12-month low of $3.18 and a 12-month high of $18.41. The business has a 50 day moving average of $14.21 and a 200-day moving average of $13.19. The stock has a market cap of $455.10 million, a PE ratio of -77.14 and a beta of 1.34.

Eton Pharmaceuticals (NASDAQ:ETON) last announced its earnings results on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, hitting the consensus estimate of ($0.02). The business had revenue of $11.65 million during the quarter, compared to the consensus estimate of $10.53 million. Eton Pharmaceuticals had a negative net margin of 15.81% and a negative return on equity of 36.29%.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC bought a new stake in shares of Eton Pharmaceuticals during the 4th quarter valued at $86,000. Jane Street Group LLC bought a new position in Eton Pharmaceuticals in the 3rd quarter valued at about $90,000. Jefferies Financial Group Inc. acquired a new position in shares of Eton Pharmaceuticals in the 4th quarter valued at approximately $133,000. Point72 Asia Singapore Pte. Ltd. lifted its holdings in shares of Eton Pharmaceuticals by 18.3% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 10,561 shares of the company’s stock worth $141,000 after acquiring an additional 1,634 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in shares of Eton Pharmaceuticals during the 4th quarter worth approximately $147,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.